Clinical trials: Embryonal Neoplasm
Glioma, Glioblastoma Multiforme
Study of DC Vaccination Against Glioblastoma
This is a Phase II study in a single center to determine the efficacy of autologous dendritic cells (DCs) loaded with autogeneic glioma stem-like cells (A2B5+) administered as a vaccination in adults with glioblastoma multiforme…
- Conditions
- Glioma, Glioblastoma Multiforme, Neoplasms
- Trial name
- NCT01567202
- Testing
- Surgery, Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Neuroendocrine Cancer, Small Cell Lung Cancer
A Study of Armored CAR T Cells in People With Cancer
The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
- Conditions
- Neuroendocrine Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC )
- Trial name
- NCT07783477
- Testing
- DLL3-SAVVYZ-IL18 CAR T cell
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Adult
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Fluorescence guidance is a safe and efficient tool for glioblastomas resection. The most widely used technique is based on 5-aminolevulinic acid (5ala), which stains glioblastoma cells through a metabolic abnormality and thus…
- Trial name
- FLEGME (NCT03291977)
- Testing
- Fluorescéine Sodique Faure, White-light surgery
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Rennes University Hospital
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2
Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or…
- Conditions
- Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2, Oligodendroglioma, Oligodendroglioma IDH-mutant and 1p/19q-codeleted
- Trial name
- NCT07712757
- Testing
- Safusidenib
- Volunteers
- 140 people
- Sponsor
- Nuvation Bio Inc.
Glioblastoma
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide…
- Trial name
- NCT02179086
- Testing
- Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide
- Where
- 237 sites in United States, Canada
- Volunteers
- 624 people
- Sponsor
- NRG Oncology
Metastatic (Stage IV) Melanoma
Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy
Therapies that target specific molecules markedly inhibit cancer growth in several malignancies, and provide valuable strategies for the treatment of advanced melanoma.
- Trial name
- AMMAM (NCT02133222)
- Testing
- blood sample
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Refractory Germ Cell Tumors, Dornase Alfa
Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.
Germ cell tumors (GCTs) are highly curable malignancies; however, a subset of patients with relapsed or refractory disease after first- and second-line chemotherapy have a very poor prognosis, with long-term survival rates below…
- Trial name
- DACT-GCT (NCT07121322)
- Testing
- dornase alfa i.v. and cisplatin
- Where
- Slovakia
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute, Slovakia
Melanoma
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
This study will examine the effectiveness and safety of glembatumumab vedotin as monotherapy or in combination with immunotherapies in patients with advanced melanoma.
- Trial name
- NCT02302339
- Testing
- glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)
- Where
- 14 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Neuroblastoma
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01493830
- Testing
- fluorescence in situ hybridization, gene expression analysis, microarray analysis
- Volunteers
- 5 people
- Sponsor
- Children's Oncology Group
Brain Tumors
Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy
Normal tissue response is critical for brain radiotherapy, especially for dose escalation which carries with it an increased incidence of radiation-induced brain injury.
- Trial name
- NCT01212237
- Testing
- fMRI Evaluation
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Pheochromocytoma, Paraganglioma
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
White adipose tissue (WAT) and brown adipose tissue (BAT) form the main adipose tissue subtypes in humans and several animals. BAT, owing to its unique metabolic function, has been of increased focus and interest in metabolic…
- Trial name
- NCT06440122
- Testing
- FDG-PET Scan
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- King's College Hospital NHS Trust
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Intracranial Tumors, Glioblastoma
A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
This research study is studying the changes in primary and metastatic brain tumor inflammation using positron emission tomography (PET) imaging using a radioactive substance called [11C] PBR28a, which is also known as peripheral…
- Conditions
- Intracranial Tumors, Glioblastoma, Melanoma
- Trial name
- NCT02431572
- Testing
- PBR PET, Cancer Immunotherapy, Radiation and chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Melanoma (Skin)
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00005875
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Safety and efficacy of Cardonilmab as a second-line or above treatment in patients with advanced malignant melanoma and renal cell carcinoma.
- Trial name
- NCT06670300
- Testing
- cardonilimab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- YongZhang
Melanoma
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Objectives: 1. To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel…
- Trial name
- NCT01295931
- Testing
- Indocyanine Green (IC-Green), Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Astrocytoma, Central Nervous System Neoplasm
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas.
- Conditions
- Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma
- Trial name
- NCT00100802
- Testing
- Laboratory Biomarker Analysis, Lomustine, Radiation Therapy
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Transcriptomics, Radiomics
Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data
This project intends to use multiple types of biological samples from glioma patients and mouse intracranial tumor models as research objects, and comprehensively apply a series of omics sequencing technologies and molecular…
- Conditions
- Transcriptomics, Radiomics, Glioma
- Trial name
- NCT04792437
- Testing
- surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Yu Yao, MD
Metastatic Uveal Melanoma
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with…
- Trial name
- NCT05415072
- Testing
- DYP688
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Urological Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment.
- Trial name
- NCT02836795
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.